Comprehensive review of factors implicated in the heterogeneity of response in depression

Depression and Anxiety

Volumn 29, Issue 4, 2012, Pages 340-354

  Carter, Gebra Cuyún ^a   Cantrell, Ronald A ^a   Zarotsky, Victoria ^b   Haynes, Virginia S ^a   Phillips, Glenn ^a   Alatorre, Carlos I ^a   Goetz, Iris ^a   Paczkowski, Rosirene ^a   Marangell, Lauren B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b OPTUM   (United States)

Author keywords

antidepressants; antidepressive agents; comorbidity; depression; heterogeneity; outcomes; review; SNRI; SSRI; TCA; treatment effect; treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LITHIUM; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE;

COMORBIDITY; CONFERENCE PAPER; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; HUMAN; MARRIAGE; PAIN; PRIORITY JOURNAL; SCORING SYSTEM; SOCIAL SUPPORT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

DEPRESSIVE DISORDER; HUMANS; TREATMENT OUTCOME;

EID: 84860645690     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21918     Document Type: Conference Paper

References (83)

1. American Psychiatric Association. Lifetime prevalence of mental disorders. Available at:. Accessed on Feb 19, 2010.
2. National Institute for Health and Clinical Excellence. The Guideline Manual-April 2006 Available at:. Accessed on Dec 01, 2009.
3. Middleton K, Hing E, Xu J,. National Hospital Ambulatory Medical Care Survey: 2005 outpatient department summary. Adv Data 2007;(389): 1-34.
4. Gabler NB, Duan N, Liao D, et al. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials 2009; 10: 43.
5. Fernandez YG, Nguyen H, Duan N, et al. Assessing heterogeneity of treatment effects: are authors misinterpreting their results ? Health Serv Res 2009; Nov 19. Epub ahead of print.
6. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010; 11: 85.
7. Fava M., Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659. (Pubitemid 39658481)
8. Greenfield S, Kravitz R, Duan N, et al. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007; 120: S3-S9. (Pubitemid 46497038)
9. Kravitz RL, Duan N, Braslow J,. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004; 82: 661-687. (Pubitemid 40143102)
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STARD report. J Clin Psychiat 2006; 67: 185-195. (Pubitemid 43357463)
11. Cantrell RA, Alatorre CI, Davis EJ, et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 2010; 12: 845-857.
12. Goetz I, Carter GC, Lucero M, et al. Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. Curr Med Res Opin 2011; 27: 697-711.
13. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-1452.
14. Joyce PR, Mulder RT, Luty SE, et al. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 2003; 108: 20-23. (Pubitemid 36783277)
15. Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004; 164: 1197-1204. (Pubitemid 39030356)
16. Zanardi R, Cusin C, Rossini D, et al. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. J Clin Psychopharmacol 2003; 23: 535-539. (Pubitemid 37443183)
17. Sakado K, Sato T, Uehara T, et al. Perceived parenting pattern and response to antidepressants in patients with major depression. J Affect Disord 1999; 52: 59-66. (Pubitemid 29232034)
18. Trivedi MH, Rush AJ, Pan JY, et al. Which depressed patients respond to nefazodone and when? J Clin Psychiat 2001; 62: 158-163. (Pubitemid 32270088)
19. Entsuah AR, Huang H, Thase ME,. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiat 2001; 62: 869-877. (Pubitemid 33131173)
20. Sonawalla SB, Farabaugh AH, Leslie VM, et al. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiat 2002; 26: 1415-1419.
21. Julian LJ, Mohr DC,. Cognitive predictors of response to treatment for depression in multiple sclerosis. J Neuropsych Clin Neurosci 2006; 18: 356-363.
22. Raskin J, Xu JY, Kajdasz DK,. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. Int Psychogeriatr 2008; 20: 309-327. (Pubitemid 351230223)
23. Saghafi R, Brown C, Butters MA, et al. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. Int J Geriatr Psychiat 2007; 22: 1141-1146. (Pubitemid 350120664)
24. Yamashita H, Fujikawa T, Yanai I, et al. Clinical features and treatment response of patients with major depression and silent cerebral infarction. Neuropsychobiology 2001; 44: 176-182. (Pubitemid 33036028)
25. Perlis RH, Alpert J, Nierenberg AA, et al. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand 2003; 108: 432-438. (Pubitemid 37452827)
26. Klein DN, Schatzberg AF, McCullough JP, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 1999; 55: 149-157.
27. Pyne JM, Bullock D, Kaplan RM, et al. Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. J Clin Psychiat 2001; 62: 261-268. (Pubitemid 32428765)
28. Driscoll HC, Basinski J, Mulsant BH, et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiat 2005; 20: 661-667. (Pubitemid 41131777)
29. Reynolds CF, III, Dew MA, Frank E, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiat 1998; 155: 795-799. (Pubitemid 28252659)
30. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiat 2002; 36: 384-391. (Pubitemid 34777988)
31. Baca E, Garcia-Garcia M, Porras-Chavarino A,. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiat 2004; 28: 57-65. (Pubitemid 37548498)
32. Mazure CM, Bruce ML, Maciejewski PK, et al. Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response. Am J Psychiat 2000; 157: 896-903. (Pubitemid 30412339)
33. Herrman H, Patrick DL, Diehr P, et al. Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study. Functional status, health service use and treatment of people with depressive symptoms. Psychol Med 2002; 32: 889-902. (Pubitemid 34823341)
34. Cheng IC, Liao SC, Lee MB, et al. Predictors of treatment response and length of stay for inpatients with major depression. J Formos Med Assoc 2007; 106: 903-910.
35. Kecskes I, Rihmer Z, Szadoczky E, et al. Does gender and coexisting anxiety influence the treatment outcome in depression? Eur J Psychiat 2003; 17: 17-21. (Pubitemid 36676092)
36. Sullivan MD, Katon WJ, Russo JE, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract 2003; 16: 22-31.
37. Arnow BA, Blasey C, Manber R, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord 2007; 97: 197-202. (Pubitemid 44937434)
38. Scheibe S, Preuschhof C, Cristi C, et al. Are there gender differences in major depression and its response to antidepressants? J Affect Disord 2003; 75: 223-235. (Pubitemid 36860026)
39. Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006; 98: 437-447. (Pubitemid 43352537)
40. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiat 1998; 55: 1128-1132. (Pubitemid 28558286)
41. Beevers CG, Wells TT, Miller IW,. Predicting response to depression treatment: the role of negative cognition. J Consult Clin Psychol 2007; 75: 422-431. (Pubitemid 47444746)
42. Blom MB, Spinhoven P, Hoffman T, et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007; 104: 119-126. (Pubitemid 350052321)
43. Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39: 145-150. (Pubitemid 39602638)
44. Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiat 1998; 59: 669-675. (Pubitemid 29068312)
45. Gildengers AG, Houck PR, Mulsant BH, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharmacol 2005; 25: S8-S13. (Pubitemid 41060240)
46. Hintikka J, Tolmunen T, Tanskanen A, et al. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiat 2003; 3: 17.
47. Cowan MJ, Freedland KE, Burg MM, et al. Predictors of treatment response for depression and inadequate social support-the ENRICHD randomized clinical trial. Psychother Psychosom 2008; 77: 27-37. (Pubitemid 350261945)
48. Bschor T, Canata B, Muller-Oerlinghausen B, et al. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 2001; 64: 261-265. (Pubitemid 32324219)
49. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Brit J Psychiat 2007; 190: 344-349. (Pubitemid 46580685)
50. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13: 18-27. (Pubitemid 32537090)
51. Sullivan MJ, Adams H, Tripp D, et al. Stage of chronicity and treatment response in patients with musculoskeletal injuries and concurrent symptoms of depression. Pain 2008; 135: 151-159. (Pubitemid 351186797)
52. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STARD report. Am J Psychiat 2008; 165: 342-351. (Pubitemid 351704490)
53. Altamura AC, Montresor C, Salvadori D, et al. Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression? A preliminary 12-month naturalistic study. Int J Neuropsychopharmacol 2004; 7: 481-487. (Pubitemid 39648078)
54. Gum AM, Arean PA, Bostrom A,. Low-income depressed older adults with psychiatric comorbidity: secondary analyses of response to psychotherapy and case management. Int J Geriatr Psychiat 2007; 22: 124-130.
55. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25: 131-138. (Pubitemid 32493829)
56. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66: 17-22. (Pubitemid 38146528)
57. Kroenke K, Shen J, Oxman TE, et al. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain 2008; 134: 209-215. (Pubitemid 350251018)
58. Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002; 43: 310-316.
59. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiat 2007; 62: 321-326. (Pubitemid 47444280)
60. Bogner HR, Cary MS, Bruce ML, et al. The role of medical comorbidity in outcome of major depression in primary care: the PROSPECT study. Am J Geriatr Psychiat 2005; 13: 861-868. (Pubitemid 46638674)
61. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiat 2003; 54: 879-883. (Pubitemid 37311349)
62. Bosworth HB, Voils CI, Potter GG, et al. The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiat 2008; 23: 129-134. (Pubitemid 351308491)
63. Petersen T, Papakostas GI, Bottonari K, et al. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiat Res 2002; 109: 9-16. (Pubitemid 34159305)
64. Quilty LC, De FF, Rolland JP, et al. Dimensional personality traits and treatment outcome in patients with major depressive disorder. J Affect Disord 2008; 108: 241-250.
65. Alpert M, Silva RR, Pouget ER,. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003; 23: 309-313. (Pubitemid 36807797)
66. Beaglehole B, Luty SE, Mulder RT, et al. Low red cell folate levels are associated with poor response to nortriptyline in major depression. Acta Neuropsychiatrica 2007; 19: 204-207. (Pubitemid 46905371)
67. Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiat 2004; 65: 1090-1095.
68. Doraiswamy PM, Khan ZM, Donahue RM, et al. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiat 2001; 9: 423-428. (Pubitemid 33015130)
69. Papakostas GI, Petersen T, Mischoulon D, et al. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiat 2003; 44: 44-50. (Pubitemid 36056773)
70. Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STARD report. Ann Clin Psychiat 2010; 22: 43-55.
71. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STARD level one treatment outcomes. Drug Alcohol Depend 2010; 107: 161-170.
72. Friedman ES, Wisniewski SR, Gilmer W, et al. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STARD trial. Depress Anxiety 2009; 26: 612-621.
73. Kashner TM, Trivedi MH, Wicker A, et al. The impact of nonclinical factors on care use for patients with depression: a STARD report. CNS Neurosci Ther 2009; 15: 320-332.
74. Kozel FA, Trivedi MH, Wisniewski SR, et al. Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a sequenced treatment alternatives to relieve depression (STARD) report. Am J Geriatr Psychiat 2008; 16: 58-64.
75. Lesser IM, Castro DB, Gaynes BN, et al. Ethnicity/race and outcome in the treatment of depression: results from STARD. Med Care 2007; 45: 1043-1051.
76. Tomba E, Grandi S, Fava GA,. Therapeutic factors in depression: new strategies. Riv Psichiatr 2009; 44: 95-101.
77. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiat 2006; 163: 28-40. (Pubitemid 43050100)
78. Warden D, Rush AJ, Wisniewski SR, et al. Income and attrition in the treatment of depression: a STARD report. Depress Anxiety 2009; 26: 622-633.
79. Zaratiegui R., STAR* D study: searching strategies regarding lack of response to an SSRI. Vertex 2009; 20: 119-128.
80. Yates WR, Mitchell J, John RA, et al. Clinical features of depression in outpatients with and without co-occurring general medical conditions in STARD: confirmatory analysis. Prim Care Companion J Clin Psychiat 2007; 9: 7-15. (Pubitemid 46280272)
81. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009 Jan 21;(1): MR000006.
82. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010; 341: c4737.
83. Sherbourne C, Schoenbaum M, Wells KB, et al. Characteristics, treatment patterns, and outcomes of persistent depression despite treatment in primary care. Gen Hosp Psychiat 2004; 26: 106-114. (Pubitemid 38369116)